Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kassiou

Showing results (191-200 of 231) with videos related to

Pageof 24
Sort By:
ACS Chemical Neuroscience|July 3, 2015
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICASamuel D Banister, Michael Moir, Jordyn Stuart, et al.
Plos One|February 19, 2013
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in ratsHervé Boutin, Christian Prenant, Renaud Maroy, et al.
Journal of Medicinal Chemistry|February 17, 2017
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in GlioblastomaQingqing Zhou, Athena F Phoa, Ramzi H Abbassi, et al.
ACS Chemical Neuroscience|April 30, 2015
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135Samuel D Banister, Jordyn Stuart, Richard C Kevin, et al.
Cell Death Discovery|April 17, 2021
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cellsAriadna Recasens, Sean J Humphrey, Michael Ellis, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 27, 2022
Quantification of the purinergic P2X<sub>7</sub> receptor with [<sup>11</sup>C]SMW139 improves through correction for brain-penetrating radiometabolitesJoachim Brumberg, Richard Aarnio, Anton Forsberg, et al.
Scientific Reports|August 15, 2020
Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulationJared S Katzeff, Fiona Bright, Kitty Lo, et al.
Biochemical Pharmacology|November 1, 2015
Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signallingAthena F Phoa, Stephen Browne, Fadi M S Gurgis, et al.
European Journal of Medicinal Chemistry|September 13, 2020
Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphismRenee Sokias, Eryn L Werry, Hei Wun Alison Cheng, et al.
ACS Chemical Neuroscience|August 26, 2017
Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X<sub>7</sub> Receptor AntagonistShane M Wilkinson, Melissa L Barron, James O'Brien-Brown, et al.
Pageof 24

Showing results (191-200 of 231) with videos related to

Sort By:
Pageof 24
ACS Chemical Neuroscience|July 3, 2015
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICASamuel D Banister, Michael Moir, Jordyn Stuart, et al.
Plos One|February 19, 2013
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in ratsHervé Boutin, Christian Prenant, Renaud Maroy, et al.
Journal of Medicinal Chemistry|February 17, 2017
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in GlioblastomaQingqing Zhou, Athena F Phoa, Ramzi H Abbassi, et al.
ACS Chemical Neuroscience|April 30, 2015
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135Samuel D Banister, Jordyn Stuart, Richard C Kevin, et al.
Cell Death Discovery|April 17, 2021
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cellsAriadna Recasens, Sean J Humphrey, Michael Ellis, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 27, 2022
Quantification of the purinergic P2X<sub>7</sub> receptor with [<sup>11</sup>C]SMW139 improves through correction for brain-penetrating radiometabolitesJoachim Brumberg, Richard Aarnio, Anton Forsberg, et al.
Scientific Reports|August 15, 2020
Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulationJared S Katzeff, Fiona Bright, Kitty Lo, et al.
Biochemical Pharmacology|November 1, 2015
Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signallingAthena F Phoa, Stephen Browne, Fadi M S Gurgis, et al.
European Journal of Medicinal Chemistry|September 13, 2020
Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphismRenee Sokias, Eryn L Werry, Hei Wun Alison Cheng, et al.
ACS Chemical Neuroscience|August 26, 2017
Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X<sub>7</sub> Receptor AntagonistShane M Wilkinson, Melissa L Barron, James O'Brien-Brown, et al.
Pageof 24